A Systematic Review of Depression and Anxiety in Adults with Pyoderma Gangrenosum.
Journal
Advances in skin & wound care
ISSN: 1538-8654
Titre abrégé: Adv Skin Wound Care
Pays: United States
ID NLM: 100911021
Informations de publication
Date de publication:
01 Aug 2021
01 Aug 2021
Historique:
entrez:
14
7
2021
pubmed:
15
7
2021
medline:
18
11
2021
Statut:
ppublish
Résumé
To synthesize the available evidence on the prevalence and odds for anxiety and depression in adults with pyoderma gangrenosum (PG). Observational studies examining anxiety and depression in adults with PG were systematically searched using the MEDLINE, EMBASE, PsycINFO, and CINAHL databases from the inception of each database to March 11, 2020. Two authors independently screened references based on predetermined eligibility criteria. Of the 244 articles identified, three met the eligibility criteria. Relevant data were extracted from included studies, and methodological quality was evaluated independently by two authors using the modified Newcastle-Ottawa Scale. Three observational studies comprising 183 participants with PG met the inclusion criteria. Estimated rates of depression in adults with PG ranged from 10% to 23%. None of the studies measured rates of anxiety. The current systematic review suggests that depression is a common psychological comorbidity in adults with PG. Additional research is required to further assess the psychological comorbidities in this population.
Identifiants
pubmed: 34260421
doi: 10.1097/01.ASW.0000755920.76330.21
pii: 00129334-202108000-00007
doi:
Types de publication
Journal Article
Systematic Review
Langues
eng
Pagination
432-436Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Ruocco A, Sangiuliano S, Gravina AG, Miranda A, Nicoletti G. Pyoderma gangrenous: an updated review. J Eur Acad Dermatol Venereol 2009;23(9):1008–17.
von den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997;137(6):1000–5.
Binus AM, Qureshi AA, Li VW, Winterfield LS. Pyoderma gangrenosum: a retrospective review of patient characteristics, comorbidities and therapy in 103 patients. Br J Dermatol 2011;165(6):1244–50.
Saracino A, Kelly R, Liew D, Chong A. Pyoderma gangrenosum requiring inpatient management: a report of 26 cases with follow up. Australas J Dermatol 2011;52(3):218–21.
Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol 2012;13(3):191–211.
Marzano AV, Borghi A, Wallach D, Cugno M. A comprehensive review of neutrophilic diseases. Clin Rev Allergy Immunol 2018;54(1):114–30.
Dalgard FJ, Gieler U, Tomas-Aragones L, et al. The psychological burden of skin diseases: a cross-sectional multicenter study among dermatological out-patients in 13 European countries. J Invest Dermatol 2015;135(4):984–91.
Farzanfar D, Dowlati Y, French L, Lowes M, Alavi A. Inflammation: a contributor to depressive comorbidity in inflammatory skin disease. Skin Pharmacol Physiol 2018;31(5):246–51.
Köhler C, Freitas T, Maes M, et al. Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 2017;135(5):373–87.
Ighani A, Al-Mutairi D, Rahmani A, Weizman AV, Piguet V, Alavi A. Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study. Br J Dermatol 2019;180(3):672–3.
Ighani A, Piguet V, Alavi A. Pyoderma gangrenosum and its impact on quality of life: a multicentre, prospective study. J Am Acad Dermatol 2018;79(3):AB19.
Craig FF, Thomas KS, Mitchell EJ, et al. UK Dermatology Clinical Trials Network’s STOP GAP trial (a multicentre trial of prednisolone versus ciclosporin for pyoderma gangrenosum): protocol for a randomised controlled trial. Trials 2012;13:1–7.
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009;6(7):e1000100.
Stang A. A critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010;25(9):603–5.
Dowlatshahi E, Wakkee M, Arends L, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol 2014;134(6):1542–51.
Machado MO, Stergiopoulos V, Maes M, et al. Depression and anxiety in adults with hidradenitis suppurativa: systematic review and meta-analysis. JAMA Dermatol 2019;155(8):939–45.
Borda LJ, Hirt PA, Shah SM, et al. Clinical manifestations, associations, and treatments of patients with pyoderma gangrenosum in a South Florida cohort: a preliminary report. J Am Acad Dermatol 2019;81(4):AB183.
Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003;289(23):3095–105.
Knoll AD, MacLennan RN. Prevalence and correlates of depression in Canada: findings from the Canadian Community Health Survey. Can Psychol 2017;58(2):116–23.
Anderson RJ, Freedland KE, Clouse RE, Lustman PJ. The prevalence of comorbid depression in adults with type I diabetes: a meta-analysis. Diabetes Care 2001;24(6):1069–78.
Dickens C, McGowan L, Clark-Carter D, Creed F. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 2002;64(1):52–60.
Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006;48(8):1527–37.
Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003;12(4):833–42.
Garg A, Chren M, Sands L, et al. Psychological stress perturbs epidermal permeability barrier homeostasis: implications for the pathogenesis of stress-associated skin disorders. Arch Dermatol 2001;137(1):53–9.
Gupta M, Jarosz P, Gupta A. Posttraumatic stress disorder (PTSD) and the dermatology patient. Clin Dermatol 2017;35(3):260–6.
Tuckman A. The potential impact of psychological skin conditions. Dermatol Ther (Heidelb) 2017;7(Suppl 1):53–7.
Woo KY. Wound-related pain: anxiety, stress and wound healing. Wounds UK 2010;6(4):92–8.
Bennett ML, Jackson JM, Jorizzo JL, Fleischer AB, White WL, Callen JP. Pyoderma gangrenosum. A comparison of typical and atypical forms with an emphasis on time to remission. Case review of 86 patients from 2 institutions. Medicine (Baltimore) 2000;79(1):37–46.
Pettersson A, Boström KB, Gustavsson P, Ekselius L. Which instruments to support diagnosis of depression have sufficient accuracy? A systematic review. Nord J Psychiatry 2015;69(7):497–508.
Kroenke K, Spitzer RL, Williams JBW. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003;41(11):1284–92.
McDonald K, Shelley AJM. The PHQ-2 in dermatology—standardized screening for depression and suicidal ideation. JAMA Dermatol 2018;154(2):139–41.
Maverakis E, Le S, Callen J, et al. New validated diagnostic criteria for pyoderma gangrenosum. J Am Acad Dermatol 2019;80(4):e87–8.
Maverakis E, Ma C, Shinkai K, et al. Diagnostic criteria of ulcerative pyoderma gangrenosum: a Delphi consensus of international experts. JAMA Dermatol 2018;154(4):461–6.
Jockenhöfer F, Wollina U, Salva KA, Benson S, Dissemond J. The PARACELSUS score: a novel diagnostic tool for pyoderma gangrenosum. Br J Dermatol 2019;180(3):615–20.